World Journal of
Clinical Cases

WJCC

World Journal of Clinical Cases

Contents

Contents

Contents

Contents

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Zaza Demetrashvili, FACS, FICS, MD, PhD, Professor, Department of Surgery, Tbilisi State Medical University, Tbilisi 0177, Georgia. zdemetr@yahoo.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (*WJCC*, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

   WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJCC* as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The *WJCC*'s CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Pediatric acute heart failure caused by endocardial fibroelastosis mimicking dilated cardiomyopathy: A case report

Yao-Ying Xie, Qiu-Li Li, Xin-Le Li, Fan Yang

Yao-Ying Xie, Xin-Le Li, College of Clinical Medicine, Inner Mongolia Minzu University, Tongliao 028000, Inner Mongolia Autonomous Region, China

Yao-Ying Xie, Fan Yang, Department of Pediatric Medical Center, Soochow University, Affiliated Hulunbuir Hospital, Hulunbuir 021000, Inner Mongolia Autonomous Region, China

Qiu-Li Li, College of Medicine, Shantou University, Shantou 515063, Guangdong Province, China

Fan Yang, School of Medicine, Shihezi University, Shihezi 832000, Xinjiang Uygur Autonomous Region, China

Corresponding author: Yao-Ying Xie, MD, MSc, PhD, Research Fellow, College of Clinical Medicine, Inner Mongolia Minzu University, No. 536 Huolinhe Street (West), Tongliao 028000, Inner Mongolia Autonomous Region, China. xieyaoying@vip.qq.com

Abstract

BACKGROUND

Endocardial fibroelastosis (EFE) is a diffuse endocardial collagen and elastin hyperplasia disease of unknown etiology, which may be accompanied by myocardial degenerative changes leading to acute or chronic heart failure. However, acute heart failure (AHF) without obvious associated triggers is rare. Prior to the report of endomyocardial biopsy, the diagnosis and treatment of EFE are highly susceptible to being confounded with other primary cardiomyopathies. Here, we report a case of pediatric AHF caused by EFE mimicking dilated cardiomyopathy (DCM), with the aim of providing a valuable reference for clinicians to early identify and diagnose EFE-induced AHF.

CASE SUMMARY

A 13-mo-old female child was admitted to hospital with retching. Chest X-ray demonstrated enhanced texture in both lungs and an enlarged heart shadow. Color doppler echocardiography showed an enlarged left heart with ventricular wall hypokinesis and decreased left heart function. Abdominal color ultrasonography revealed a markedly enlarged liver. Pending the result of the endomyocardial biopsy report, the child was treated with a variety of resuscitative measures including nasal cannula for oxygen, intramuscular sedation with chlorpromazine and promethazine, cedilanid for cardiac contractility enhancement, and diuretic treatment with furosemide. Subsequently, the child's endomyocardial biopsy report result was confirmed as EFE. After the above early

interventions, the child's condition gradually stabilized and improved. One week later, the child was discharged. During a 9-mo follow-up period, the child took intermittent low-dose oral digoxin with no signs of recurrence or exacerbation of the heart failure.

CONCLUSION

Our report suggests that EFE-induced pediatric AHF may present in children over 1 year of age without any apparent precipitants, and that the associated clinical presentations are grossly similar to that of pediatric DCM. Nonetheless, it is still possible to be diagnosed effectively on the basis of the comprehensive analysis of auxiliary inspection findings before the result of the endomyocardial biopsy is reported.

Key Words: Endocardial fibroelastosis; Dilated cardiomyopathy; Pediatric; Acute heart failure; Early identification and diagnosis

Core Tip: Prior to the report of endomyocardial biopsy, the diagnosis and treatment of endocardial fibroelastosis (EFE) is highly susceptible to be confounded with other primary cardiomyopathies. Herein, we report a case of pediatric acute heart failure (AHF) caused by EFE mimicking dilated cardiomyopathy, aiming to provide a valuable reference for clinicians to early identify and diagnose EFE-induced AHF.

INTRODUCTION

Pediatric endocardial fibroelastosis (EFE) is a kind of primary infantile cardiomyopathy, also known as endocardial sclerosis[1]. While various theories have been proposed in recent years in relation to the pathogenesis of EFE, the exact etiology of EFE remains unknown[2]. At present, most scholars believe that it is associated with the immune inflammatory response caused by viral infection[3]. More than 60% of children with onset are younger than 1 year of age[4]. The clinical manifestations of infants under 6 mo of age are principally acute heart failure (AHF), while the clinical manifestations of infants 6 to 12 mo of age are principally chronic heart failure (CHF), and often occurs after respiratory infections [5]. The symptoms and signs of AHF caused by EFE greatly resemble those of the acute exacerbations of dilated cardiomyopathy (DCM) in pediatric patients[5]. However, the treatment options for these two conditions clinically are not exactly identical, and early misdiagnosis may have potentially unintended consequences for the subsequent therapy of the children[6]. More importantly, it is relatively rare for children with EFE over 1 year of age to develop AHF suddenly without any notable triggers or other directly related underlying diseases[7].

Here, we report a case of pediatric AHF caused by EFE mimicking DCM, in which the child was preliminarily diagnosed with EFE based on critical auxiliary examinations encompassing chest radiography, electrocardiography and echocardiography alone before the result of the endomyocardial biopsy was available, and complete clinical remission was achieved with early and correct interventions. By reporting this case, we hope to provide clinicians who are under-resourced for specific subspecialty pathological biopsies with additional empiric references in terms of early screening and differentiating when encountering children with EFE confused with DCM, and to remain vigilant for those children's clinical manifestations.

CASE PRESENTATION

Chief complaints

A 13-mo-old female child was admitted to our hospital with retching for 1 wk and worsening condition for 2 d.

History of present illness

The child had experienced retching without apparent triggers for 1 wk prior to presentation at our hospital, but no vomiting. The child's family denied that the child had a history of fever, rash, cough and expectoration, jaundice, diarrhea, and trauma. Outpatient blood assays revealed hemoglobin (HGB) 84.00 g/L, C-reactive protein (CRP) 0.30 mg/L, and carbon dioxide combining power (CO_2CP) 15.70 mmol/L. During the course of the illness, the child had poor appetite, poor sleep, fair mental status, and reduced urine output, but there was no abnormal exhaust and defecation. The child had no other concomitant symptoms, including any signs of upper respiratory tract infection.

History of past illness

The child was hospitalized in our neonatology unit 1 year ago with a diagnosis of neonatal hyperbilirubinemia (NHB), neonatal bilirubin encephalopathy (NBE), congenital hepatic cyst (CHC), and congenital bilateral renal multiple cysts (CRMCs). NHB and NBE recovered favorably after active treatment. CHC and CRMC were treated with conservative observation, and color ultrasonography of the liver and kidneys were conducted every other year. Anemia was detected at 8 mo of age, with a minimum HGB of about 34 g/L. After treatment with oral medication and dietary therapy, the maximum HGB was about 80 g/L. The child had no previous history of surgery or blood transfusion.

Personal and family history

The child was born of a gravida 1, parity 1 mother. She was delivered vaginally at 38^{+2} wk of gestation, with a birth weight of 2750 g. She was breastfed, with normal growth and developmental milestones and no significant history of medication or food allergies. The child's parents were healthy, and there was no abnormality in the family history.

Physical examination

The child was 74 cm tall and weighed 9.5 kg, with body temperature 36.4 °C, pulse rate 150/min, respiration rate 68/min, blood pressure 77/64 mmHg, and poor general status, tachypnea, anemic appearance. Physical examination showed coarse breath sounds in both lungs, low and dull heart sounds, heart rate 150/min, galloping rhythm, a pansystolic grade 3 murmur in the precardiac area, and the lower border of the liver reaching the right pelvic inlet.

Laboratory examinations

The relevant blood tests of the child after admission are illustrated in Table 1. A number of laboratory test indicators, including HGB, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration and ferritin concentration, were decreased. Biomarkers of heart failure such as N-Terminal pro-brain natriuretic peptide were remarkably elevated. No abnormal results were found in urine and stool analyses.

Imaging examinations

Chest X-ray demonstrated enhanced texture in both lungs and enlarged heart shadow, with a cardiothoracic ratio of about 0.62 (Figure 1A). Electrocardiogram (ECG) suggested left axis deviation, paroxysmal supraventricular tachycardia with a heart rate of 150/min and ST-T segment changes. Color doppler echocardiography (CDE) displayed enlarged left heart, thickening of the posterior wall of the left ventricle, minor amounts of mitral regurgitation, ventricular wall hypokinesis and decreased left heart function (Figure 1B-D). Cardiac magnetic resonance (CMR) revealed slight endocardial thickening of the left ventricle, minor thickening of the myocardium, and diffuse motion reduction of the ventricular wall with no apparent delayed enhancement abnormalities (Figure 1E and F). Color ultrasonography of the abdomen showed hepatic cyst (size: 0.93 cm × 0.75 cm), bilateral renal multiple cysts (the largest one size: 1.1 cm × 1.7 cm) and a markedly enlarged liver with a right oblique diameter of 8.25 cm and an inferior hepatic border 6.32 cm from the right inferior costal arch border of the midclavicular line (Figure 2A and B).

FINAL DIAGNOSIS

We arranged emergency consultations with multiple disciplines encompassing respiratory medicine, cardiology, hematology, and nursing. According to the clinical symptoms, signs, laboratory examinations, imaging examinations, relevant medical history, age of onset, and rapid development of the condition, the child was preliminarily diagnosed with pediatric AHF caused by EFE. And the result of the final endomyocardial biopsy report also confirmed our diagnosis (Figure 2C and D).

Table 1 Some blood routine and blood biochemistry tests of the child

Test item	Day 1	Day 3	Day 7
WBC	10.11×10^9/L (4.4-11.0)	9.32×10^9/L (4.4-11.0)	8.68×10^9/L (4.4-11.0)
RBC	4.84×10^{12}/L (4.0-5.5)	4.77×10^{12}/L (4.0-5.5)	4.82×10^{12}/L (4.0-5.5)
HGB	84 g/L (112-149)	82 g/L (112-149)	83 g/L (112-149)
HCT	30.7% (34-43)	33.5% (34-43)	38.1% (34-43)
MCV	63.4 fL (76-88)	62.8 fL (76-88)	63.0 fL (76-88)
MCH	17.4 pg (24-30)	16.9 pg (24-30)	17.2 pg (24-30)
MCHC	274 g/L (310-355)	271 g/L (310-355)	273 g/L (310-355)
PLT	522×10^9/L (188-472)	487×10^9/L (188-472)	445×10^9/L (188-472)
LYMPH%	56.3% (23-69)	44.1% (23-69)	40.7% (23-69)
MONO%	7.2% (2-11)	8.1% (2-11)	8.6% (2-11)
NEUT%	34.0% (22-65)	36.7% (22-65)	33.15% (22-65)
LYMPH#	5.69×10^9/L (1.8-6.3)	4.42×10^9/L (1.8-6.3)	4.05×10^9/L (1.8-6.3)
MONO#	0.73×10^9/L (0.12-0.80)	0.80×10^9/L (0.12-0.80)	0.87×10^9/L (0.12-0.80)
NEUT#	3.44×10^9/L (1.2-7.0)	3.65×10^9/L (1.2-7.0)	3.34×10^9/L (1.2-7.0)
RDW-CV	20.4% (10.9-15.0)	19.4% (10.9-15.0)	17.6% (10.9-15.0)
FER	8.11 ng/mL (15.0-150.0)	8.10 ng/mL (15.0-150.0)	8.10 ng/mL (15.0-150.0)
VB$_{12}$	362.40 pg/mL (197.00-771.00)	348.67 pg/mL (197.00-771.00)	384.22 pg/mL (197.00-771.00)
Folate	18.77 ng/mL (3.89-26.80)	18.03 ng/mL (3.89-26.80)	19.55 ng/mL (3.89-26.80)
CRP	0.3 mg/L (0.0-1.0)	0.2 mg/L (0.0-1.0)	0.05 mg/L (0.0-1.0)
IgG	10.43 g/L (7.00-16.00)	8.27 g/L (7.00-16.00)	9.01 g/L (7.00-16.00)
IgA	1.30 g/L (0.70-4.00)	1.55 g/L (0.70-4.00)	1.41 g/L (0.70-4.00)
IgM	1.73 g/L (0.40-2.30)	1.66 g/L (0.40-2.30)	1.80 g/L (0.40-2.30)
C3	1.56 g/L (0.90-1.80)	1.31 g/L (0.90-1.80)	1.45 g/L (0.90-1.80)
C4	0.32 g/L (0.10-0.40)	0.30 g/L (0.10-0.40)	0.29 g/L (0.10-0.40)
ASO	96 IU/mL (0-170)	83 IU/mL (0-170)	79 IU/mL (0-170)
ESR	16 mm/h (0-20)	14 mm/h (0-20)	12 mm/h (0-20)
PCT	0.12 ng/mL (< 0.05)	0.07 ng/mL (< 0.05)	0.03 ng/mL (< 0.05)
NT-proBNP	893.15 ng/L	517.40 ng/L	190.64 ng/L
Ca	2.65 mmol/L (2.10-2.80)	2.50 mmol/L (2.10-2.80)	2.69 mmol/L (2.10-2.80)
K	4.36 mmol/L (3.70-5.20)	4.62 mmol/L (3.70-5.20)	4.57 mmol/L (3.70-5.20)
Na	139.70 mmol/L (135.00-145.00)	142.74 mmol/L (135.00-145.00)	140.32 mmol/L (135.00-145.00)
Cl	102.80 mmol/L (96.00-108.00)	105.71 mmol/L (96.00-108.00)	103.40 mmol/L (96.00-108.00)
AMY	50.0 U/L (35.0-135.0)	62.0 U/L (35.0-135.0)	57.0 U/L (35.0-135.0)
CO$_2$CP	15.7 mmol/L (22.0-29.0)	21.1 mmol/L (22.0-29.0)	25.8 mmol/L (22.0-29.0)
ALT	11.0 U/L (7.0-30.0)	10.3 U/L (7.0-30.0)	9.0 U/L (7.0-30.0)
AST	39.0 U/L (15.0-40.0)	36.7 U/L (15.0-40.0)	29.4 U/L (15.0-40.0)
AST/ALT	3.55	3.56	3.27
LDH	394.0 U/L (120.0-250.0)	376.0 U/L (120.0-250.0)	285.0 U/L (120.0-250.0)
CK	100.0 U/L (50.0-310.0)	84.0 U/L (50.0-310.0)	77.0 U/L (50.0-310.0)
CK-MB	23.5 U/L (0.0-25.0)	20.9 U/L (0.0-25.0)	18.4 U/L (0.0-25.0)
α-HBDH	331.0 U/L (72.0-182.0)	255.4 U/L (72.0-182.0)	191.1 U/L (72.0-182.0)

GLU	5.35 mmol/L (3.90-6.10)	5.62 mmol/L (3.90-6.10)	5.05 mmol/L (3.90-6.10)
BUN	3.2 mmol/L (2.7-7.0)	2.9 mmol/L (2.7-7.0)	2.7 mmol/L (2.7-7.0)
CREA	22.2 μmol/L (19.0-44.0)	21.4 μmol/L (19.0-44.0)	20.1 μmol/L (19.0-44.0)

α-HBDH: α-hydroxybutyrate dehydrogenase; ALT: Alanine aminotransferase; AMY: Amylase; ASO: Anti-streptolysin O; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; C3: Complement C3; C4: Complement C4; Ca: Calcium; CO_2CP: Carbon dioxide combining power; CK: Creatine kinase; CK-MB: Creatine kinase MB isoenzyme; Cl: Chlorine; CREA: Creatinine; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; FER: Ferritin; GLU: Glucose; HCT: Hematocrit; HGB: Hemoglobin; IgA: Immunoglobulin A; IgG: Immunoglobulin G; IgM: Immunoglobulin M; K: Kalium; LDH: Lactate dehydrogenase; LYMPH%: Lymphocyte ratio; LYMPH#: Lymphocyte count; MCH: Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; MCV: Mean corpuscular volume; MONO%: Monocyte ratio; Na: Natrium; NEUT%: Neutrophil ratio; NEUT#: Neutrophil count; PCT: Procalcitonin; NT-proBNP: N-terminal pro-brain natriuretic peptide; PLT: Platelet; MONO#: Monocyte count; RBC: Red blood cell; RDW-CV: Red cell distribution width-coefficient of variation; VB_{12}: Vitamin B_{12}; WBC: White blood cell.


DOI: 10.12998/wjcc.v11.i8.1771 **Copyright** ©The Author(s) 2023.

Figure 1 Chest radiograph, color doppler echocardiography, and cardiac magnetic resonance of the child. A: Prominently enlarged heart with a high cardiothoracic ratio; B: Marked enlargement of the left ventricle (inner diameter 38.70 mm) with diffuse slight thickening of the endocardium; C: Thickening of the posterior wall of the left ventricle (purple arrow); D: A small amount of mitral regurgitation (yellow arrow); E: Bright-blood T_1-weighted image shows slight endocardial thickening of the left ventricle and slight thickening of the myocardium (orange arrow); F: Dark-blood T_2-weighted image shows diffuse ventricular wall hypokinesis without visible delayed enhancement abnormalities (orange arrow).

TREATMENT

As per the standard pediatric advanced life support guidelines, the child was immediately resuscitated and monitored for vital signs, and administered oxygen by nasal cannula (oxygen flow rate: 6 L/min), sedated with chlorpromazine 1 mg/kg and promethazine 1 mg/kg by intramuscular (i.m.) injection, enhanced cardiac contractility with 10 μg/kg cedilanid by intravenous (i.v.) push (half of the total amount given for the first time and the remaining amount given in two divided doses, every 6 h), prompted diuresis with 0.1 mg/kg furosemide by i.v. push (given every 6 h), and relieved bronchospasm and reduced myocardial edema with 0.5 mg/kg dexamethasone by i.v. drip[8]. After the above resuscitation measures, the child fell asleep quietly with heart rate 147/min, respiration rate 43/min, and percutaneous oxygen saturation 95%-99%, under the bedside monitor. In view of the potential for adverse reactions of either oral or i.v. iron supplementation to adversely affect the child's rescue, we managed her anemia with regular dietary iron supplementation during hospitalization. Day 2 ward rounds, the child was in poor general condition with coarse breath sounds in both lungs, low and dull heart sounds, but stable breathing, and a heart rate of 140/min after activity. Cedilanid was given as a maintenance dose for consolidation therapy, vitamin C was administered intravenously for nourishing the myocardium, and changes in the condition were closely observed. Day 3 ward rounds, the child's

Figure 2 Abdominal color ultrasonography and endomyocardial biopsy for the child. A and B: Congestive hepatomegaly with a right oblique diameter of 8.25 cm and an inferior hepatic border 6.32 cm from the right inferior costal arch border of the midclavicular line; C and D: Endomyocardial biopsy shows diffuse elastin and collagen hyperplasia (black arrow).

general condition improved with stable respiration, breathing rate 45/min, strong and rhythmic heart sounds, and heart rate 120/min. The inferior hepatic border was located approximately 3 cm at the inferior costal arch border of the right midclavicular line, and the hepatomegaly was visibly retracted. Bedside CDE demonstrated that the enlarged left heart began to shrink. After that, low-dose cedilanid was continued for maintenance therapy, and the heart rate status was monitored. Day 4 ward rounds, the child's condition was relatively stable, with heart rate 105-120/min at rest and percutaneous oxygen saturation above 95%. The relevant blood tests were reexamined and all laboratory indicators gradually returned to normal. The maintained dose of cedilanid was given again to continue the treatment, and subtle changes in the condition were monitored. Day 7 ward rounds, the vital signs of the child were stable and the breath was slightly tachypnea, with heart rate 116/min and respiration rate 41/min, under the bedside monitor. The inferior hepatic border was located about 2 cm at the inferior costal arch border of the right midclavicular line, and the spleen was not palpated under the left rib. There was no edema in both lower extremities of the child post treatment and the capillary refill time was around 2 s. On the same day, the relevant blood tests were reexamined again and a number of laboratory test indicators, encompassing hematocrit, CRP and CO_2CP, returned to normal.

OUTCOME AND FOLLOW-UP

After correct, timely, and effective treatment, the child was discharged on day 7 after admission without any complications. The reexamination result of chest X-ray showed that the enlarged heart shadow was slightly retracted (Figure 3A). Similarly, the computed tomography (CT) reexamination results of thorax and abdomen revealed that the size of enlarged heart was marginally retracted, and the hepatomegaly was visibly retracted (Figure 3B and C). After the child was discharged from our hospital, her anemia improved dramatically with a combination of oral drug (ferrous gluconate: 3 mg per time, three times 1 d) and dietary iron supplementation manners. Except for this, the child took intermittent low-dose oral digoxin (0.05 mg per time, once every 12 h) with no signs of recurrence or exacerbation of the heart failure, within a 9-mo follow-up period. The timeline of the child's visit is illustrated in Figure 4.

DISCUSSION

EFE is one of the important causes of heart failure in infants and toddlers. It occurs in 1/5000 live births and accounts for 1% to 2% of congenital heart disease, which has an unknown etiology and genetic characteristics, can occur in the absence of cardiac malformations[6,9]. The younger the age of onset of the children with EFE, the worse the prognosis and the higher the mortality[10]. Due to the lack of specificity in the presentation of this disease, it is prone to be confounded with pneumonia and myocarditis and other diseases, so the clinical diagnosis before the result of the endomyocardial biopsy report is difficult, especially when combined with other primary cardiomyopathies that can cause left ventricular enlargement, the clinical presentation of EFE may be masked, with a high risk of missed diagnosis and misdiagnosis[10].

Evidence-based medicine has indicated that AHF caused by EFE has a devastating course and severe prognosis[11]. The gold standard for the diagnosis and differential diagnosis of EFE is the endomyocardial biopsy; however, the biopsy result requires a long waiting time[12]. During this time window, clinicians often first need to refer to chest radiographs, ECGs, CDEs and related laboratory examinations for initial diagnosis and early patient management, which is a great test of clinicians' personal competences and experience levels. Currently, no practical guidelines on the diagnosis and treatment of EFE prior to the tissue biopsy result have been released internationally by national heart associations

Figure 3 Chest X-ray and thoracic and abdominal computed tomography re-examination results of the child before discharge. A and B: Mild cardiac retraction; C: Remarkable retraction of the previously enlarged liver.

worldwide. The discrimination of pediatric AHF caused by EFE from other diseases with similar clinical symptoms and manifestations is therefore very challenging, especially for DCM in infants and young children[13].

Children younger than 1 year of age or even younger with primary EFE are more likely to be exactly diagnosed according to the age distribution of the onset of pediatric heart diseases[14-16]. Yet, in rare-onset children older than 1 year of age, the manifestation of EFE's cardiac imaging examinations are almost identical to those of early onset DCM in infants and toddlers[17]. Both show a sudden dilatation of a single heart cavity (*e.g.*, the left ventricle) on chest X-ray or chest CT. On a more accurate CDE inspection, both also exhibit the same ventricular wall hypokinesis, varying degrees of ventricular wall thickening, cardiac valve regurgitation, and left heart dysfunction. And more important, the blood-related tests of both present with assay indicators of AHF without any specificity. These things together make it easy for pediatric AHF caused by EFE to be masqueraded as DCM[10].

In our case, this 13-mo-old female child suddenly developed AHR without any triggers and without any history of infection, cardiac malformation, and other underlying cardiovascular disease. This is relatively rare in clinical practice, as many studies suggest that respiratory infections and congenital cardiovascular malformations are important triggers and potential initiators in the development of AHF caused by EFE[10]. We had considered pediatric DCM before the available endomyocardial biopsy result was returned, yet the echocardiographic findings just showed a diffuse and uniform slight thickening of the left ventricular endocardium with echo dense and enhanced, and a clear demarcation between ventricular endocardium and myocardium, a slight thickening of the myocardium, only a small amount of mitral regurgitation, a left ventricular end-diastolic dimension of 42 mm (< 50 mm). In parallel, both bright-blood T_1-weighted image sequences and black-blood T_2-weighted image sequences of the CMR examination of the child demonstrated a general thickening of the endocardium. In fact, for DCM, the possible thickening of the ventricular wall will not appear on the endocardium, but rather more on the thickening of the myocardium, and there are no non-functional fibrotic changes similar to EFE with this thickening. In such cases, when DCM presents with AHF, it is possible that the indicators of left ventricular systolic function on the CDE may not be much decreased. Furthermore, though the ECG manifestations of both DCM and EFE in infants and toddlers are left ventricular high voltage, poor R-wave progression, ST-T segment changes, and various different arrhythmias, the primary character-istics of the former are typically atrial tachycardia and atrial fibrillation. These are all distinctly different from EFE. Of note, the bedside CDE on the 3rd day of admission suggested that the dilated left heart had begun to show retraction, but this is almost impossible in DCM. Because despite the fact that DCM can be relieved, it is difficult to reduce the size of the heart to normal. Combined with the child's age of onset, family history, and the findings of consultations with physicians from different departments, we unanimously agreed that EFE should be given a higher diagnostic priority. With more evidence pointing to EFE, we made a preliminary diagnosis of pediatric AHF caused by EFE prior to the result of the tissue biopsy was reported, which bought valuable time for early timely and correct intervention in the progression of the child's disease. More importantly, both the rapid improvement of the child's condition after treatment and the result of the endomyocardial biopsy report ultimately confirmed that our judgment was correct.

Unfortunately, no directed therapeutic approach for EFE is known since the rarity of the condition [18]. Yet, recovery of the enlarged heart and lost cardiac function in children with EFE is possible, and current clinically recommended treatment typically follows a standardized and vigorous decongestive therapy based on cardiac glycosides[19]. The child followed such a treatment principle from admission to the 9-mo follow-up cut-off point after discharge, and this hospital and domiciliary treatment has helped her well to maintain the sustainability of the decongestive therapy. In recent years, long-term follow-up studies have shown that bioimmunotherapy increases the clinical benefit of children with EFE and helps to improve endocardial hyperplasia and fibrosis[20]. Given the risk of future infection of the

Figure 4 Timeline of the child's visit, hospitalization, and postdischarge follow-up. CDE: Color doppler echocardiography; CO$_2$CP: Carbon dioxide combining power; CRP: C-reactive protein; DCM: Dilated cardiomyopathy; HGB: Hemoglobin; i.m.: Intramuscular; i.v.: Intravenous; EFE: Endocardial fibroelastosis.

child's hepatic and renal cysts and the underlying physical conditions, there was no opportunity to apply steroid hormones or other biological immunomodulators to her. However, we still recommend the use of biological immunomodulators for those children with EFE who have indications, because they may improve the prognosis of heart failure. Compared with EFE, while DCM is also treated in the acute exacerbation phase using a heart failure management approach, it is generally managed with long-term diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and beta-blockers to control its progression of CHF and ventricular remodeling due to the irreversibility of cardiac enlargement and decline in cardiac function[21]. Additionally, though bioimmunotherapy for adult DCM seems to benefit a proportion of patients, to date such treatments have not raised sufficient promise for pediatric DCM, and there is no evidence that steroid hormones use reduce mortality and morbidity in children with DCM[22]. As a result, the treatment regimens for EFE and DCM in infants and toddlers are not always identical, and early misdiagnosis improper treatment may have potentially unintended consequences for the children's prognosis.

In infant and young childhood, EFE frequently presents with DCM and unfavorable progression, which makes it difficult for clinicians to distinguish these two diseases[6,23]. While the case we report is successful in differentiating EFE from DCM prior to the pathology report result, this is based more on extensive clinical work experience[24,25]. Limited by the objective one-sidedness of individual information, the early identification of such pediatric AHF caused by EFE masquerading as DCM still requires more clinical medical record information and data support.

CONCLUSION

Here, we report a case of pediatric AHF caused by EFE masquerading as DCM, which was accurately identified early in the course of the disease, for which we demonstrate that a primary diagnosis for EFE before the result of the endomyocardial biopsy is entirely possible. We hope that our report will give clinicians more decision support and attract sufficient attention when diagnosing similar diseases.

ACKNOWLEDGEMENTS

FOOTNOTES

ORCID number: Yao-Ying Xie 0000-0001-9981-356X; Qiu-Li Li 0000-0003-1752-9552; Xin-Le Li 0000-0001-8833-853X; Fan Yang 0000-0002-4566-2353.

REFERENCES

1   **Ren MY**, Ren LH. Research progress of endocardial fibroelastosis[J]. *Xinxueguan Kangfu Yixue Zazhi* 2020; **29**: 723-726 [DOI: 10.3969/j.issn.1008-0074.2020.06.19]

2   **Xu X**, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, Iascone M, Kalluri R, Zeisberg M, Del Nido PJ, Zeisberg EM. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. *Circ Res* 2015; **116**: 857-866 [PMID: 25587097 DOI: 10.1161/CIRCRESAHA.116.305629]

3   **Seki A**, Patel S, Ashraf S, Perens G, Fishbein MC. Primary endocardial fibroelastosis: an underappreciated cause of cardiomyopathy in children. *Cardiovasc Pathol* 2013; **22**: 345-350 [PMID: 23518027 DOI: 10.1016/j.carpath.2013.02.003]

4   **Zhang Yong**, Sun Lingli and Li Tao. Clinical features and outcomes of endocardial fibroelastosis in 60 children[J]. *Zhongguo Fuyou Jiankang Yanjiu* 2014; **5**: 790-792 [DOI: 10.3969/j.issn.1673-5293.2014.05.028]

5   **Pan Y**, Liu XY. Prevalence and predictors of left ventricular reverse remodeling after drug therapy in children with new-onset dilated cardiomyopathy[J]. *Journal of Clinical Pediatrics* 2020; **38**: 851-856 [DOI: 10.3969/j.issn.1000-3606.2020.11.012]

6   **Luca AC**, Lozneanu L, Miron IC, Trandafir LM, Cojocaru E, Pădureț IA, Mihăilă D, Leon-Constantin MM, Chiriac Ș, Iordache AC, Țarcă E. Endocardial fibroelastosis and dilated cardiomyopathy - the past and future of the interface between histology and genetics. *Rom J Morphol Embryol* 2020; **61**: 999-1005 [PMID: 34171049 DOI: 10.47162/RJME.61.4.02]

7   **Zhao Y**, Wang LK, Eskin A, Kang X, Fajardo VM, Mehta Z, Pineles S, Schmidt RJ, Nagiel A, Satou G, Garg M, Federman M, Reardon LC, Lee SL, Biniwale R, Grody WW, Halnon N, Khanlou N, Quintero-Rivera F, Alejos JC, Nakano A, Fishbein GA, Van Arsdell GS, Nelson SF, Touma M. Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome. *J Mol Med (Berl)* 2021; **99**: 1623-1638 [PMID: 34387706 DOI: 10.1007/s00109-021-02112-z]

8   **Jiao M**, Han L, Wang HL, Jin M, Wang XF, Zheng K, Liang YM, Xiao YY. A long-term follow-up study on the clinical treatment of 75 cases with primary endocardial fibroelastosis [J]. *Zhonghua Erke Zazhi* 2010; **48**: 603-609 [DOI: 10.3760/cma.j.issn.0578-1310.2010.08.011]

9   **Ren SH**, Qu R, Xiao YJ. Progress of endocardial fibroelastosis[J]. *Zhongguo Xiaoer Jijiu Yixue* 2012; **19**: 437-439 [DOI: 10.3760/cma.j.issn.1673-4912.2012.04.035]

10   **Arya SO**, Karpawich PP, Gupta P, Buddhe S, Singh HR, Hussein Y, Gowda ST. Primary endocardial fibroelastosis presenting in a young child as incessant ventricular tachycardia and dilated cardiomyopathy. *Tex Heart Inst J* 2012; **39**: 714-718 [PMID: 23109776]

11   **Jarrar M**, Vaksmann G, Godart F, Rey C, Dupuis C. [Natural history and prognostic factors in primary endocardial fibroelastosis in infants]. *Arch Mal Coeur Vaiss* 1994; **87**: 653-656 [PMID: 7857189]

12   **Narayan R**, Menahem S, Chow CW, Dennett X. Endomyocardial biopsy in infants and children with cardiomyopathy. *Clin Cardiol* 1991; **14**: 903-907 [PMID: 1764827 DOI: 10.1002/clc.4960141109]

13   **Ponce CC**, Dinamarco PV. Primary endocardial fibroelastosis and nonimmune hydrops fetalis: case report with autopsy. *Fetal Pediatr Pathol* 2015; **34**: 136-139 [PMID: 25517884 DOI: 10.3109/15513815.2014.987936]

14   **Moons P**, Bratt EL, De Backer J, Goossens E, Hornung T, Tutarel O, Zühlke L, Araujo JJ, Callus E, Gabriel H, Shahid N, Sliwa K, Verstappen A, Yang HL, Thomet C. Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (ACNAP), the ESC Working Group on Adult Congenital Heart Disease (WG ACHD), the Association for European Paediatric and Congenital Cardiology (AEPC), the Pan-African Society of Cardiology (PASCAR), the Asia-Pacific Pediatric Cardiac Society (APPCS), the Inter-American Society of Cardiology (IASC), the Cardiac Society of Australia and New Zealand (CSANZ), the International Society for Adult Congenital Heart Disease (ISACHD), the World Heart Federation (WHF), the European Congenital Heart Disease Organisation (ECHDO), and the Global Alliance for Rheumatic and Congenital Hearts (Global ARCH). *Eur Heart J* 2021; **42**: 4213-4223 [PMID: 34198319 DOI: 10.1093/eurheartj/ehab388]

15   **Liu Y**, Chen S, Zühlke L, Black GC, Choy MK, Li N, Keavney BD. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol* 2019; **48**: 455-463 [PMID: 30783674 DOI: 10.1093/ije/dyz009]

16   **Liu Y**, Chen S, Zühlke L, Babu-Narayan SV, Black GC, Choy MK, Li N, Keavney BD. Global prevalence of congenital heart disease in school-age children: a meta-analysis and systematic review. *BMC Cardiovasc Disord* 2020; **20**: 488 [PMID: 33213369 DOI: 10.1186/s12872-020-01781-x]

17   **Writing Group**, Sachdeva R, Valente AM, Armstrong AK, Cook SC, Han BK, Lopez L, Lui GK, Pickard SS, Powell AJ; Rating Panel, Bhave NM, Sachdeva R, Valente AM, Pickard SS, Baffa JM, Banka P, Cohen SB, Glickstein JS, Kanter JP, Kanter RJ, Kim YY, Kipps AK, Latson LA, Lin JP, Parra DA, Rodriguez FH 3rd, Saarel EV, Srivastava S, Stephenson EA, Stout KK, Zaidi AN; Solution Set Oversight Committee, Gluckman TJ, Aggarwal NR, Bhave NM, Dehmer GJ, Gilbert ON, Kumbhani DJ, Price AL, Winchester DE, Gulati M; Appropriate Use Criteria Task Force, Dehmer GJ, Doherty JU, Bhave NM, Daugherty SL, Dean LS, Desai MY, Gillam LD, Mehrotra P, Sachdeva R, Winchester DE. ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use Criteria for Multimodality Imaging During the Follow-Up Care of Patients With Congenital Heart Disease: A Report of the American College of Cardiology Solution Set Oversight Committee and Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Pediatric Echocardiography. *J Am Soc Echocardiogr* 2020; **33**: e1-e48 [PMID: 33010859 DOI:

10.1016/j.echo.2020.04.026]

18   **Ozdemir D**, Cortopassi IO, McNamara RL. An illustrative case of endocardial fibroelastosis and recalcitrant intracardiac thrombosis: A case report. *Thromb J* 2019; **17**: 8 [PMID: 31182935 DOI: 10.1186/s12959-019-0199-3]

19   **Manning JA**, Sellers FJ, Bynum RS, Keith JD. The Medical Management of Clinical Endocardial Fibroelastosis. *Circulation* 1964; **29**: 60-65 [PMID: 14105031 DOI: 10.1161/01.cir.29.1.60]

20   **Jiao M**, Han L, Wang HL, Jin M, Wang XF, Zheng K, Liang YM, Xiao YY. [A long-term follow-up study on the clinical treatment of 75 cases with primary endocardial fibroelastosis]. *Zhonghua Er Ke Za Zhi* 2010; **48**: 603-609 [PMID: 21055306]

21   **Weintraub RG**, Semsarian C, Macdonald P. Dilated cardiomyopathy. *Lancet* 2017; **390**: 400-414 [PMID: 28190577 DOI: 10.1016/S0140-6736(16)31713-5]

22   **Soares P**, Rocha G, Pissarra S, Soares H, Flôr-de-Lima F, Costa S, Moura C, Dória S, Guimarães H. Neonatal dilated cardiomyopathy. *Rev Port Cardiol* 2017; **36**: 201-214 [PMID: 28256370 DOI: 10.1016/j.repc.2016.10.007]

23   **Shimada S**, Robles C, Illigens BM, Casar Berazaluce AM, del Nido PJ, Friehs I. Distention of the Immature Left Ventricle Triggers Development of Endocardial Fibroelastosis: An Animal Model of Endocardial Fibroelastosis Introducing Morphopathological Features of Evolving Fetal Hypoplastic Left Heart Syndrome. *Biomed Res Int* 2015; **2015**: 462469 [PMID: 26064914 DOI: 10.1155/2015/462469]

24   **Raboisson MJ**, Fouron JC, Sonesson SE, Nyman M, Proulx F, Gamache S. Fetal Doppler echocardiographic diagnosis and successful steroid therapy of Luciani-Wenckebach phenomenon and endocardial fibroelastosis related to maternal anti-Ro and anti-La antibodies. *J Am Soc Echocardiogr* 2005; **18**: 375-380 [PMID: 15846168 DOI: 10.1016/j.echo.2004.10.023]

25   **Weiner Z**, Shalev E. Doppler fetal echocardiography in endocardial fibroelastosis. *Obstet Gynecol* 2001; **98**: 933-935 [PMID: 11704210 DOI: 10.1016/s0029-7844(01)01505-8]

Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: https://www.f6publishing.com/helpdesk

https://www.wjgnet.com